Activity Overview

This educational activity is an archive of the live presentation held on May 31, 2026.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, advanced practice professionals, pathologists, oncology nurses, and other health care practitioners who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Select among available next-generation endocrine monotherapies and combination strategies for patients with ESR1-mutant, HR+/HER2– advanced breast cancer after CDK4/6 inhibitor progression based on clinical trial data, mutation profile, and patient-specific factors
Evaluate the rationale and emerging evidence for positioning next-generation endocrine agents in the frontline metastatic setting for HR+/HER2– advanced breast cancer
Interpret emerging clinical trial data for oral SERDs and PROTACs in early-stage, HR+/HER2– breast cancer to identify patients who may benefit from adjuvant or neoadjuvant next-generation endocrine strategies

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Stemline Therapeutics, Inc; and Rigel Pharmaceuticals, Inc.

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

GET STARTED WITH THIS PROGRAM:

Related Content

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society